JP2006523682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523682A5 JP2006523682A5 JP2006507478A JP2006507478A JP2006523682A5 JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5 JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006507478 A JP2006507478 A JP 2006507478A JP 2006523682 A5 JP2006523682 A5 JP 2006523682A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- agonist
- polypeptide
- subject
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45692003P | 2003-03-21 | 2003-03-21 | |
| PCT/US2004/008833 WO2004084835A2 (en) | 2003-03-21 | 2004-03-22 | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523682A JP2006523682A (ja) | 2006-10-19 |
| JP2006523682A5 true JP2006523682A5 (https=) | 2007-06-07 |
Family
ID=33098171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507478A Pending JP2006523682A (ja) | 2003-03-21 | 2004-03-22 | インターロイキン−２１／インターロイキン−２１受容体のアゴニストを用いた免疫学的障害の治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060159655A1 (https=) |
| EP (1) | EP1608315A4 (https=) |
| JP (1) | JP2006523682A (https=) |
| KR (1) | KR20060015482A (https=) |
| CN (1) | CN1849131A (https=) |
| AU (1) | AU2004224277A1 (https=) |
| BR (1) | BRPI0408523A (https=) |
| CA (1) | CA2518854A1 (https=) |
| CO (1) | CO5611161A2 (https=) |
| CR (1) | CR7994A (https=) |
| EC (1) | ECSP056027A (https=) |
| IL (1) | IL198102A0 (https=) |
| MX (1) | MXPA05010035A (https=) |
| NO (1) | NO20054343L (https=) |
| RU (1) | RU2005132458A (https=) |
| WO (1) | WO2004084835A2 (https=) |
| ZA (1) | ZA200507235B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| CA2604222A1 (en) * | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| WO2007111714A2 (en) * | 2005-11-28 | 2007-10-04 | Zymogenetics, Inc. | Il-21 antagonists |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| US8178097B2 (en) * | 2008-05-23 | 2012-05-15 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
| US20100075329A1 (en) * | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| CA2740077A1 (en) * | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
| CA2798739A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
| EP3502236B1 (en) * | 2011-02-18 | 2023-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| AU2016341529B2 (en) | 2015-10-22 | 2023-03-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US12600757B2 (en) | 2017-04-07 | 2026-04-14 | Bioniz Therapeutics, Inc. | Peptides inhibiting gamma-c-cytokine activity and methods of use |
| KR102454376B1 (ko) * | 2018-07-04 | 2022-10-17 | 서울대학교산학협력단 | 신경손상의 면역세포치료 |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| CA3137971A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| EP4146669A4 (en) * | 2020-05-08 | 2024-06-05 | Alastin Skincare, Inc. | Compositions and methods for modulating inflammation and wound healing |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| CN120813605A (zh) * | 2023-01-06 | 2025-10-17 | 泰温治疗私人有限公司 | 抗原结合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| EP1082433A4 (en) * | 1998-05-29 | 2003-01-02 | Human Genome Sciences Inc | Interleukins 21 and 22 |
| AU5104799A (en) * | 1998-08-04 | 2000-02-28 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ES2629395T3 (es) * | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
| ES2334338T3 (es) * | 2001-11-05 | 2010-03-09 | Zymogenetics, Inc. | Antagonistas de il-21. |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| DK1531850T3 (da) * | 2002-06-07 | 2012-06-04 | Zymogenetics Inc | Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| RU2007102287A (ru) * | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
| US7533965B2 (en) * | 2005-03-07 | 2009-05-19 | Eastman Kodak Company | Apparatus and method for electrostatically charging fluid drops |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2004
- 2004-03-22 CA CA002518854A patent/CA2518854A1/en not_active Abandoned
- 2004-03-22 CN CNA2004800076306A patent/CN1849131A/zh active Pending
- 2004-03-22 MX MXPA05010035A patent/MXPA05010035A/es unknown
- 2004-03-22 EP EP04758055A patent/EP1608315A4/en not_active Withdrawn
- 2004-03-22 ZA ZA200507235A patent/ZA200507235B/en unknown
- 2004-03-22 RU RU2005132458/13A patent/RU2005132458A/ru unknown
- 2004-03-22 BR BRPI0408523-0A patent/BRPI0408523A/pt not_active IP Right Cessation
- 2004-03-22 KR KR1020057017652A patent/KR20060015482A/ko not_active Withdrawn
- 2004-03-22 AU AU2004224277A patent/AU2004224277A1/en not_active Abandoned
- 2004-03-22 WO PCT/US2004/008833 patent/WO2004084835A2/en not_active Ceased
- 2004-03-22 US US10/806,611 patent/US20060159655A1/en not_active Abandoned
- 2004-03-22 JP JP2006507478A patent/JP2006523682A/ja active Pending
-
2005
- 2005-09-16 CR CR7994A patent/CR7994A/es not_active Application Discontinuation
- 2005-09-20 EC EC2005006027A patent/ECSP056027A/es unknown
- 2005-09-20 NO NO20054343A patent/NO20054343L/no not_active Application Discontinuation
- 2005-09-21 CO CO05095726A patent/CO5611161A2/es unknown
-
2009
- 2009-04-07 IL IL198102A patent/IL198102A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523682A5 (https=) | ||
| RU2005132458A (ru) | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 | |
| Okiyama et al. | Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A | |
| Soriano et al. | IL-1β biological treatment of familial Mediterranean fever | |
| US20090092604A1 (en) | Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity | |
| RU2411042C2 (ru) | Композиции и способы для лечения острого респираторного синдрома (sars) | |
| US20060024268A1 (en) | Modulation of immunoglobulin production and atopic disorders | |
| EP1137766B1 (en) | Use of il-12 antibodies to treat psoriasis | |
| US20110002928A1 (en) | Uses of Mammalian Cytokine; Related Reagents | |
| JP2013227340A (ja) | 可溶性リンホトキシンβレセプターによる脱髄障害の処置 | |
| JP2010132660A5 (https=) | ||
| DE112012000404T5 (de) | Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer | |
| HK1220605A1 (zh) | 使用抗il23抗体治疗克罗恩氏病的方法 | |
| Campbell et al. | Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute‐phase response | |
| Hess et al. | High doses of interleukin‐12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant | |
| KR20230086674A (ko) | 파킨슨 질환의 치료 | |
| JP2016527326A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| Selmaj | Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system | |
| Lauenstein et al. | Pituitary adenylate cyclase‐activating peptide receptor 1 mediates anti‐inflammatory effects in allergic airway inflammation in mice | |
| CN121177504A (zh) | 靶向刺激免疫分子在制备预防和治疗自然衰老药物、保健品和化妆品中的用途 | |
| JP2019501925A (ja) | Ｇｄｆ１１での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する | |
| US20230364192A1 (en) | Modulation of beta cell regeneration through gpr75 signaling | |
| KR20210042138A (ko) | 건선 치료 방법 | |
| HUP0100105A2 (hu) | TNF-antagonisták alkalmazása szeptikus betegségek kezelésére szolgáló gyógyszerként | |
| TW202532439A (zh) | 治療氣喘之方法 |